Which GLP-1 works best? New meta-study puts them head-to-head

(NEXSTAR) – A new study from the University of Georgia put popular GLP-1 medications head-to-head, testing which one is the most effective for weight loss.

The study compared three types of the medication: tirzepatide (better known under the brand names Zepbound and Mounjaro), semaglutide (sold as Wegovy and Ozempic), and liraglutide (aka Saxenda and Victoza).

The study looked at weight loss results in 14,000 non-diabetic patients. The findings of the meta-analysis were pretty clear, its authors say: tirzepatide takes the cake.

Tirzepatide is made by pharmaceutical company Eli Lilly as two products, one for weight loss (Zepbound) and the other for diabetes (Mounjaro).

With Zepbound, patients lost more than 20% of their starting weight. With Wegovy (aka semaglutide), it was closer to 15% of body weight........

© The Hill